Verrica Pharmaceuticals resubmits NDA for VP-102 in molluscum contagiosum

Verrica Pharmaceuticals resubmitted the New Drug Application for VP-102 for the treatment of molluscum contagiosum to the U.S. Food and Drug Administration. Ted White, President and CEO, said, "We believe the successful tech transfer of our bulk solution manufacturing addresses the only deficiency in our previous filing that resulted in our Complete Response Letter last year. We look forward to working with the FDA through the review process, and if approved, bringing VP-102 to patients as the first FDA-approved treatment option for molluscum."